TIDMSBI

RNS Number : 0075P

SourceBio International PLC

15 June 2022

SourceBio International plc

('SourceBio', the 'Company' or the 'Group')

Result of Annual General Meeting

SourceBio confirms that all resolutions put to the 2022 Annual General Meeting held on the 15 June were

duly passed by the required majority.

Voting on the resolutions was as follows:

 
 Resolution   Description                                      For   Against   Withheld 
              To receive and approve the Company's 
               Annual Report and Accounts for 
               the financial year ended 31 December 
               2021 together with the Directors' 
               Report (including the Strategic 
 1             Report) and the Auditor's Report.        54,501,649     1,500        500 
             ----------------------------------------  -----------  --------  --------- 
              To receive and approve the Directors' 
               Remuneration Report for the financial 
 2             year ended 31 December 2021.             54,496,283     6,866        500 
             ----------------------------------------  -----------  --------  --------- 
              To re-appoint RSM UK Audit LLP 
               as auditor of the Company and 
               to authorise the Directors to 
 3             fix their remuneration.                  54,501,499     1,650        500 
             ----------------------------------------  -----------  --------  --------- 
              To authorise the Directors generally 
               to allot ordinary shares up to 
 4             the specified limit.                     54,488,761    14,388        500 
             ----------------------------------------  -----------  --------  --------- 
              To empower the Directors to issue 
               shares free from statutory pre-emption 
 5 *           rights up to the specified limit.        54,454,524    20,202     28,923 
             ----------------------------------------  -----------  --------  --------- 
              To authorise the Directors to 
               make market purchases of ordinary 
 6 *           shares to the specified limit.           54,497,703     5,446        500 
             ----------------------------------------  -----------  --------  ---------

* Special Resolution

A trading update was released at 7.00am this morning.

Notes:

-- Any proxy appointments which gave direction to the Executive Chairman have been included in the "for" column;

   --    The total number of shares in issue is 74,183,038

Contacts:

 
 SourceBio International plc                            www.sourcebiointernational.com 
 Jay LeCoque, Executive Chairman                                       Via Walbrook PR 
 Tony Ratcliffe, Chief Financial Officer 
 
 Liberum (Nominated Advisor and Broker)                             Tel: 020 3100 2000 
 Richard Lindley / William Hall / Miquela 
  Bezuidenhoudt 
 
 Walbrook PR Limited                    Tel: 020 7933 8780 or sourcebio@walbrookpr.com 
 Paul McManus / Sam Allen                                   Mob: 07980 541 893 / 07502 
                                                                               558 258

About SourceBio International plc www.sourcebiointernational.com

SourceBio is a leading international provider of integrated state-of-the-art laboratory services with clients in the pharmaceutical, healthcare, clinical, drug development and life sciences research industries, with a focus on improving patient diagnosis, management and care. Group revenues are derived from four business units:

 
 --   Healthcare Diagnostics - histopathology cancer screening and clinical 
       diagnostic services for the NHS and private healthcare providers 
       across the UK and Ireland, including Digital Pathology 
 --   Genomics - DNA sequencing services and Precision Medicine offering 
       for pharmaceutical and biotechnology companies, academia, contract 
       research organisations (CROs) and other research groups in the UK, 
       Europe and North America 
     ------------------------------------------------------------------------- 
 --   Stability Storage - shelf-life testing services and equipment service 
       and validation for pharmaceutical and biotechnology companies, contract 
       manufacturers and analytical testing companies from around the world 
       but primarily in the UK, Ireland and the USA 
     ------------------------------------------------------------------------- 
 --   Infectious Disease Testing - a range of COVID-19 testing services 
       for commercial enterprises, private healthcare groups and the NHS, 
       including PCR testing under ISO 15189 accreditation. 
     -------------------------------------------------------------------------

More details on Group operations can be found here: www.sourcebioscience.com

SourceBio International plc (SBI) is listed on the AIM market of the London Stock Exchange.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGUVUURUOUNAAR

(END) Dow Jones Newswires

June 15, 2022 08:23 ET (12:23 GMT)

Sourcebio (LSE:SBI)
Historical Stock Chart
From Nov 2024 to Dec 2024 Click Here for more Sourcebio Charts.
Sourcebio (LSE:SBI)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more Sourcebio Charts.